EPO Upholds Stay on Mirrx Patent Proceedings as Santaris Pushes Ahead with HCV Rx | GenomeWeb

By Doug Macron

The European Patent Office last week upheld a request by Santaris Pharma to stay a review of a patent application at the heart of a Danish legal battle with Mirrx Pharma, stating that it would not be appropriate to make a decision on the IP until the litigation had been resolved.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.